Danuglipron

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is Danuglipron?

Danuglipron (PF-06882961) is a non-peptide, orally bioavailable small molecule agonist of the glucagon-like peptide-1 receptor (GLP-1R), developed by Pfizer. Unlike injectable GLP-1 receptor agonists such as semaglutide and liraglutide, danuglipron was designed from the ground up as a pill — representing a fundamentally different chemical approach to GLP-1 receptor activation.[1][2]

The development of oral small-molecule GLP-1 agonists has been described as a potential “second GLP-1 revolution,” addressing the injection burden that limits uptake of current peptide-based therapies. Danuglipron has completed phase 2 clinical trials in both type 2 diabetes and obesity, generating significant interest as one of the first non-peptide GLP-1 agonists with substantial human data.[3]

Compound Profile

What Does Danuglipron Actually Do?

Danuglipron activates the GLP-1 receptor — the same target as injectable peptide agonists like semaglutide — producing appetite reduction, improved glycaemic control, and weight loss. In a phase 2 dose-ranging trial in adults with obesity, danuglipron demonstrated statistically significant, dose-dependent weight loss compared to placebo over 32 weeks.[1]

The clinical profile mirrors injectable GLP-1 agonists in direction but differs in magnitude. Weight loss achieved with danuglipron in phase 2 trials was meaningful but more modest than the results seen with high-dose injectable semaglutide or tirzepatide. This is a common pattern with first-generation oral GLP-1 agonists, where pharmacokinetic challenges limit achievable receptor activation levels.[2][4]

How Danuglipron Works

Danuglipron binds the GLP-1 receptor at a site partially overlapping with but distinct from the orthosteric binding site used by native GLP-1 and peptide agonists. Cryo-EM structural studies have revealed how danuglipron and related small molecules interact with GLP-1R, showing they access an extracellular binding pocket that accommodates their non-peptide structure.[5]

Appetite suppression: GLP-1R activation in the hypothalamus and brainstem reduces appetite through established anorexigenic pathways, including suppression of NPY/AgRP neurons and activation of POMC/CART pathways — the same mechanism as injectable GLP-1 agonists.

Glycaemic control: GLP-1R activation on pancreatic beta cells enhances glucose-dependent insulin secretion (incretin effect), improving postprandial glucose handling without causing hypoglycaemia in the absence of elevated glucose.

Gastric emptying: GLP-1R agonism slows gastric emptying, contributing to both satiety and glycaemic improvements but also to the gastrointestinal side effects common to this drug class.

Biased agonism considerations: Research has explored whether danuglipron exhibits biased agonism — preferentially activating certain intracellular pathways over others compared to native GLP-1. Molecular docking studies suggest potential interactions beyond the canonical GLP-1R, including the endocannabinoid system, though these findings are preliminary.[6]

Appetite & Weight Management Context

Danuglipron’s primary research context is appetite and weight management. The phase 2 obesity trial demonstrated dose-dependent weight loss, with the highest dose group achieving clinically meaningful reductions in body weight over 32 weeks.[1]

Systematic review and meta-analysis of danuglipron alongside other non-peptide GLP-1R agonists (including orforglipron) has characterised the efficacy and safety profile of this new drug class. Gastrointestinal side effects — nausea, vomiting, diarrhoea — follow the same pattern as injectable GLP-1 agonists, driven by the pharmacological mechanism rather than the route of administration.[4]

The oral formulation represents a significant practical advantage for weight management, where treatment adherence over months to years is critical for sustained outcomes. Compare with semaglutide and tirzepatide for injectable GLP-1 comparisons, or see the Appetite & Weight Management goal page.

Metabolic Health / Insulin Sensitivity Context

GLP-1R agonism has established benefits for metabolic health and insulin sensitivity, and danuglipron’s type 2 diabetes clinical data falls squarely within this context. GLP-1R activation improves glucose homeostasis through glucose-dependent insulin secretion enhancement, glucagon suppression, and potential beta cell preservation effects.[2]

Reviews of the GLP-1R agonist class position danuglipron among emerging oral options for type 2 diabetes management, noting the potential to expand GLP-1 therapy access to patients who decline injectable treatment.[3][7]

Whether danuglipron’s metabolic effects match the magnitude of injectable GLP-1 agonists remains a key clinical question. Early data suggests comparable glycaemic improvements at tolerated doses, but the oral pharmacokinetic limitations may constrain maximal efficacy. See the Metabolic Health goal page for broader context.

Danuglipron Benefits

• Oral administration: Eliminates the injection requirement that limits GLP-1 therapy uptake — a significant practical and patient-preference advantage.[1][3]
• Clinically proven weight loss: Phase 2 trial demonstrated dose-dependent, statistically significant weight reduction in adults with obesity.[1]
• Glycaemic improvement: GLP-1R activation provides glucose-dependent insulin secretion enhancement without hypoglycaemia risk.[2]
• Small molecule stability: Unlike peptide GLP-1 agonists, danuglipron does not require cold-chain storage or protection from degradation, simplifying manufacturing and distribution.
• Established mechanism: Acts through the same receptor and pathways as clinically validated injectable GLP-1 agonists with extensive safety and efficacy records.[3]

Danuglipron Side Effects

Phase 2 clinical trial data provides a reasonable safety characterisation:

• Gastrointestinal effects: Nausea, vomiting, and diarrhoea are the most common adverse events — consistent with the GLP-1R agonist class mechanism. Rates were dose-dependent and led to discontinuation in some participants.[1][4]
• Twice-daily dosing burden: The current formulation requires twice-daily dosing due to danuglipron’s relatively short half-life. A modified-release formulation is under development to enable once-daily dosing.[2]
• Hepatic effects: Liver enzyme elevations were reported in some trial participants, prompting monitoring recommendations.
• Dose titration required: Like injectable GLP-1 agonists, slow dose escalation is needed to manage gastrointestinal tolerability.
• No cardiovascular signal: No concerning cardiovascular signals emerged in phase 2 data, though formal cardiovascular outcome trials have not been conducted.

Half-Life

Danuglipron has a plasma half-life of approximately 6–8 hours, necessitating twice-daily oral dosing in the current immediate-release formulation. This is substantially shorter than injectable GLP-1 agonists (semaglutide: ~7 days; liraglutide: ~13 hours) and has been identified as a key limitation for clinical competitiveness.[2]

Pfizer has been developing a modified-release formulation to extend the dosing interval to once daily, addressing the compliance challenge of twice-daily administration. The pharmacokinetic profile reflects the general challenge of achieving sustained receptor activation with orally administered small molecules.

Limits of Current Evidence

• No phase 3 data: Danuglipron’s clinical development has faced setbacks. Pfizer discontinued the twice-daily formulation development and is pursuing a modified-release version, creating uncertainty about the timeline for phase 3 trials.
• Modest efficacy compared to injectables: Phase 2 weight loss magnitude was lower than injectable semaglutide or tirzepatide, raising questions about competitive positioning.
• Tolerability challenges: Gastrointestinal side effect rates were significant, and the need for twice-daily dosing added compliance burden.
• Development uncertainty: Pfizer’s decision to pivot to a modified-release formulation indicates the current form may not be commercially viable.
• Limited long-term data: Trial durations were 26–32 weeks. Long-term efficacy maintenance, safety, and weight regain patterns are unknown.

Verdict

Danuglipron represents an important proof-of-concept: a non-peptide, orally bioavailable molecule that activates the GLP-1 receptor and produces clinically meaningful weight loss and glycaemic improvement. That achievement is pharmacologically significant — creating a pill that mimics the effects of a 39-amino acid peptide is not trivial.

However, the clinical reality is that first-generation oral GLP-1 agonists face substantial headwinds: modest efficacy relative to injectable leaders, challenging twice-daily dosing, and significant gastrointestinal tolerability issues. Pfizer’s pivot to a modified-release formulation acknowledges these limitations. Danuglipron’s ultimate clinical role depends on whether formulation improvements can close the efficacy and convenience gaps with injectable GLP-1 agonists and competing oral candidates like orforglipron.

FAQ

What is danuglipron?

Danuglipron (PF-06882961) is Pfizer’s oral, non-peptide GLP-1 receptor agonist. Unlike injectable GLP-1 drugs like semaglutide, danuglipron is a small molecule pill that activates the same receptor to reduce appetite, improve blood sugar control, and promote weight loss.

Is danuglipron approved?

No. Danuglipron is not approved in any country. It has completed phase 2 clinical trials in obesity and type 2 diabetes. Pfizer discontinued the twice-daily formulation and is developing a modified-release once-daily version for further clinical trials.

How does danuglipron compare to semaglutide?

Semaglutide is an injectable peptide with a ~7 day half-life, enabling weekly dosing and producing substantial weight loss (up to ~15% in trials). Danuglipron is an oral small molecule with a ~6-8 hour half-life, requiring twice-daily dosing and producing more modest weight loss in phase 2 trials. They target the same receptor but differ in chemistry, administration, and efficacy magnitude.

What are danuglipron side effects?

The most common side effects in clinical trials were gastrointestinal: nausea, vomiting, and diarrhoea — the same pattern seen with all GLP-1 receptor agonists. These effects were dose-dependent and led to discontinuation in some participants. Liver enzyme elevations were also reported.

Why did Pfizer stop danuglipron?

Pfizer discontinued development of the twice-daily immediate-release formulation of danuglipron, citing the dosing burden and tolerability profile. The company is pursuing a modified-release formulation to enable once-daily dosing, which may address these commercial viability concerns.

Is danuglipron a peptide?

No. Despite targeting the same receptor as peptide GLP-1 agonists, danuglipron is technically a small molecule (non-peptide). It is included on PeptideGuide because it acts through peptide-relevant receptor pathways and is frequently compared with peptide-based GLP-1 therapeutics.

References

1. Buckeridge C, et al. Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging study. Diabetes Obes Metab. 2025. PMID: 40539310
2. Tolkacheva EV, et al. “Next-in-class” GLP-1R Danuglipron- and Lotiglipron-like Agonists: A Patent Review (2020-2024). Curr Med Chem. 2025. PMID: 40873282
3. Brazil R. Companies seek second GLP-1 revolution — in pill form. Science. 2025. PMID: 40245133
4. Bhattarai HB, et al. Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis. Medicine. 2025. PMID: 41465949
5. Xu M, et al. Exploring Conformational Transitions in Biased and Balanced Ligand Binding of GLP-1R. Molecules. 2025. PMID: 40807391
6. Dailey KA, et al. Molecular docking of danuglipron uncovers potential crossovers between GLP-1R and the endocannabinoid system. microPublication Biology. 2025. PMID: 40838124
7. Son JW, et al. Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. Endocr Rev. 2026. PMID: 41054801